Stock Ratings / Health Care / LITS / dividends

EDSA (42) NNVC (33) NSRX (36) ACET (36) ⌘ Pro Terminal →

Lite Strategy Inc. (LITS) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.17 -4.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.16

Lite Strategy Inc. (LITS) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $35.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.16 (-1.07%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LITS)Realized 20D OHLCV Swing Band: ±12.1%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY LITS SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (31% of score)

Altman Z-Score 11.68 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (24% of score)

FRED Regime × Technicals: 31% of 52W Range • RSI-14 at 44 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.27-9.4% Next Q

Q2 (-2Q)

Grade D$1.15+0.9% Next Q

Q3 (-1Q)

Grade D$1.16+0.9% Next Q

Current

Grade D-$1.17-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LITS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LITS currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.17) and Max Pain ($1.23) forces dealer call-delta covering toward $2.37.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LITS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LITS Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LITS)

✓Walkthrough of LITS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LITS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.74%▲ ASCENDING CHANNEL

2026-10-30O $1.17H $1.17L $1.10C $1.17VOL 270.5K

RES: $1.75SUP: $1.03SMA50: $1.17SMA200: $1.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LITS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LITS Butterfly Map → + Track LITS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LITS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LITS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LITS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LITS)

Health Care Rank #589 of 1016 ⚔️ EDSA vs LITS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LITS vs. EDSA, NNVC, NSRX, ACET)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lite Strategy Inc. (LITS) ranks #589 by composite RQD confidence (42/100, grade D-) and #788 by equity capitalization ($35.6M). Within this direct 5-issuer industry benchmark cohort, LITS leads on earnings valuation at N/A trailing P/E, while LITS leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. LITS currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LITS ACTIVE Lite Strategy Inc.	D-	42/100	—	—	-18.9%	-4.88%	$35.6M	Benchmark Subject
EDSA Edesa Biotech Inc.	D-	42/100	—	—	-35.0%	+5.47%	$36.5M	/edsa-vs-lits →
NNVC NanoViricides Inc.	E	33/100	—	—	-35.0%	-1.38%	$36.5M	/nnvc-vs-lits →
NSRX Nasus Pharma Ltd.	D-	36/100	—	—	-35.0%	-4.49%	$37.4M	/nsrx-vs-lits →
ACET Adicet Bio Inc.	D-	36/100	—	—	-35.0%	-6.04%	$33.5M	/acet-vs-lits →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001262104

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Lite Strategy Inc. (LITS) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $65.3M , and -100.0% cumulative change since FY2023) , GAAP net income of -$15.9M, operating cash flow of -$20.8M, and free cash flow of -$20.8M (+58.7% YoY). On the balance sheet, LITS closed FY2025 with $82.9M in total assets against $0 in total debt (Altman Z-Score: 11.68, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$0	-$15.9M	-$20.8M	-$20.8M	$82.9M	—
FY2024 (FY)	2024-06-30	$65.3M	$18.0M	-$50.5M	-$50.5M	$24.4M	—
FY2023 (FY)	2023-06-30	$48.8M	-$32.0M	-$52.5M	-$52.5M	—	—

3. LITS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LITS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lite Strategy Inc. (NASDAQ: LITS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.17 (-4.88% 1D, market cap $35.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LITS ranks #589 in composite RQD confidence.

How does LITS compare to EDSA and NNVC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LITS carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.9%. By comparison, EDSA (Edesa Biotech Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $36.5M) and NNVC (NanoViricides Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $36.5M). Among the 5-stock peer group, LITS leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LITS?

Per LITS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001262104), Lite Strategy Inc. generated $0 in revenue (-100.0% YoY), -$15.9M in net income, and -$20.8M in free cash flow against $82.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LITS trading relative to its 50-day, 200-day, and 52-week technical levels?

LITS last traded at $1.17 (-4.88% on volume of 341,057 shares), positioning the stock 0.00% above its 50-day simple moving average ($1.17) and +7.34% above its 200-day simple moving average ($1.09). Across its 52-week range of $0.69 to $2.26, LITS sits at the 30.6% percentile with a 14-day RSI of 44.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($1.03 to $1.31).

LITS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does LITS pay a dividend and is it safe?

Lite Strategy Inc. (LITS) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: LITS RQD Cockpit LITS 12M Forecast LITS Earnings & Move LITS Dividends & DRIP LITS Insiders & 13F LITS Whale Options LITS Profit Sankey LITS News & Why